Cutaneous T-cell Lymphoma

Updated: July 12, 2024

Mail Whatsapp PDF Image

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 

carmustine

10

mg

Topical

once daily for 7–14 weeks and maximum continue up to 17 weeks, after six weeks, if there is an inadequate response, then the second course of topical therapy is administered with a dose of 20 mg once daily for 4 to 8 weeks until it is tolerable



pralatrexate

15

mg/m^2

Intravenous (IV)

once weekly for 3 – 4 weeks cycle; continue until unacceptable toxicity or disease progression.



Dose Adjustments

Adjustment in case of renal impairment:
eGFR > 30 ml/minute/1.73m2: No dose adjustment needed
eGFR 15 to 30 ml/minute/1.73m2: reduce the dose to 15 mg/m2
Avoid the use of pralatrexate for patients with end-stage renal disease, including dialysis.
Discontinue the treatment in patients with grade 3 or 4 hepatotoxicity.

vorinostat

Indicated for the treatment of CTCL, who have progressive, persistent, or recurrent disease on or followed by two systemic therapies :

400

mg

Orally

once a day

the dose is reduced to 300 mg orally per day if the patient is intolerant to therapy
the dose was further reduced to 300 mg once daily for five consecutive days each week if needed
continue the treatment until progressive disease or unacceptable toxicity occurs



Dose Adjustments

Renal Dose Adjustments:
Caution recommended.
Liver Dose Adjustments:
starting dose reduced to 300 mg orally once daily for mild to moderate hepatic impairment bilirubin 1-3 x ULN or AST > ULN
Data not available for severe hepatic impairment bilirubin > 3 x ULN

romidepsin

Indicated for the treatment of CTCL and peripheral T-cell lymphoma (PTCL) in patients who have received at least one before systemic therapy :

14

mg/m^2

Intravenous (IV)

over 4 hr

on days 1, 8, and 15 for a 28-day cycle course
Continue to repeat the cycle every 28 days till the patient's disease progression or intolerable toxicity occurs



alitretinoin topical 

Apply every 12 hours to the cutaneous lesion



methoxsalen 

orally Take orally with food or milk 2 hour before exposure to UVA
0.6 mg/kg initially
administer initial dose combined with 10 mg after 24 hr, if serum concentration <50 ng/mL
Parenteral 200 mcg (10 mL) inject into the photoactivation bag for UVAR photopheresis system



bexarotene 

300 mg/m² orally daily with the food; titrate according to toxicity or response; if there is no improvement after 8 weeks of treatment, increase the dose to 400 mg/m2/day
Topical: Apply on to the lesions every alternate day for one week, following may increase every week to every 4 times a day.
Monitor: thyroid function, cholesterol levels, and WBCs.
Sezary Syndrome or Refractory Mycosis Fungoides (Off-label)
75-150 mg orally daily in combination with the PUVA; should not exceed more than 300 mg/day



Dose Adjustments

Hepatic Impairment
use caution; Not known
Renal Impairment
use caution; Not known

mechlorethamine topical 

Put a layer of thin film of gel on upper surface of the skin to impacted areas one time a day
Dosage Modifications
Skin toxicities
After 7 days at every 3 days, can raise the frequency to alternate days for a minimum of 7 days, and then to once per day if it is bearable
Administration
Apply once or inside half-hour after elimination from the fridge and put back gel to the fridge at once after every use
Apply to absolutely dry skin at least four hours earlier
Allow targeted regions to dry for 5 to 10 minutes after application earlier than protecting with clothing
Emollients can be implemented to the targeted regions 2 hour earlier
Avoid flame, smoking and fire till the gel has dried
Avoid dressings on regions of skin where gel is used



chlormethine 

Indicated for Mycosis fungoides-type cutaneous T-cell lymphoma:

On affected skin, apply a thin layer once a day



 
 

chlormethine 

Indicated for Mycosis fungoides-type cutaneous T-cell lymphoma:

On affected skin, apply a thin layer once a day



Media Gallary

References

Content loading

Latest Posts

Cutaneous T-cell Lymphoma

Updated : July 12, 2024

Mail Whatsapp PDF Image



Free CME credits

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

Digital Certificate PDF

On course completion, you will receive a full-sized presentation quality digital certificate.

medtigo Simulation

A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

medtigo Points

medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
 
  • Registration with medtigo = 10 points
  • 1 visit to medtigo’s website = 1 point
  • Interacting with medtigo posts (through comments/clinical cases etc.) = 5 points
  • Attempting a game = 1 point
  • Community Forum post/reply = 5 points

    *Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.

All Your Certificates in One Place

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.

Our Certificate Courses